Pyrromethene Boron Difluorides in PDT

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1993
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
22044
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Dekk-tec, Inc.
3839 Ulloa Street, New Orleans, LA, 70119
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
Lee Roy Morgan
(504) 488-5415
Business Contact:
() -
Research Institution:
n/a
Abstract
The overall objective is to develop new anticancer agents which are cytotoxic in photodynamic therapy (PDT). It has been shown by Morgan and Boyer that pyrromethene boron difluoride (P-BF2) complexes can offer this property. In Phase I, substituted (P-BF2) complexes will be prepared, characterized and evaluated for PDT potentials. Studies have documented that human ovarian cancer cells (LS-2) cultured with the disodium salt of pentamethylpyrromethene-2, 6-disulfonate boron difluoride (PMPDS-BF2) plus exposure to light produced cell growth inhibition. In addition, when PMPDS-BF2 was injected intratumor into the DMBA-rat breast cancer model, followed by exposure to quartz lamp irradiation, 50-100% tumor remissions occurred. Cyano, bistetramethylene and acetoxymethyl substituted P-BF2 complexes will be evaluated in vitro and in vivo in mouse and rat tumor models. The P-BF complexes are considered to be quasiaromatic electron impoverished (QA-eI) heterocycles. They show high extinction coefficients, high fluorescent quantum yields; those with superior laser action poses little to no triplet-triplet absorption in the fluorescence spectral region. These properties will be considered and attempts to associate them to PDT will be made.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government